VIDEO: Aptiom improves quality of life, reduces seizures in patients with epilepsy

BOSTON — Two studies presented at the American Academy of Neurology meeting showed treatment with Aptiom improved quality of life scores and reduced frequency in patients with focal seizures.

Todd Grinnell, executive director of medical and scientific affairs at Sunovion Pharmaceuticals, maker of Aptiom (eslicarbazepine acetate), discusses the Sunovion-funded study results in this Healio video.

“Focal seizures are the most common type of epilepsy,” he said. “[They] are less likely to be associated with seizure freedom than generalized epilepsy, and this can impose substantial burden on patients, particularly in domains that relate to concern about when the next seizure may occur.”

In the Cantu study, patients treated with Aptiom showed improvement in cognitive function, seizure worry and social function all 31 Quality of Life in Epilepsy Inventory categories, Grinnell said.

In the Chung study, “Aptiom was associated with improved responder rates and increased time to first seizure compared to placebo,” he said.

References:

• Cantu D, et al. Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Pooled analysis from 3 phase 3 open-label extension studies. Presented at American Academy of Neurology annual meeting; April 22-27, 2023; Boston.
• Chung S, et al. Efficacy, safety and tolerability of adjunctive eslicarbazepine acetate in focal seizure patients with focal to bilateral tonic-clinic seizures at baseline. Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.